Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.

James L. Januzzi,Faiez Zannad,Stefan D. Anker,Javed Butler,Gerasimos Filippatos,Stuart J. Pocock,João Pedro Ferreira,Naveed Sattar,Subodh Verma,Ola Vedin,Janet Schnee,Tomoko Iwata,Dan Cotton,Milton Packer,EMPEROR-Reduced Trial Committees,investigators

Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.

2021

James L. Januzzi
Faiez Zannad
Stefan D. Anker
Javed Butler
Gerasimos Filippatos
Stuart J. Pocock
João Pedro Ferreira
Naveed Sattar
Subodh Verma
Ola Vedin
Janet Schnee
Tomoko Iwata
Dan Cotton
Milton Packer
EMPEROR-Reduced Trial Committees
investigators

Abstract Background The relationship between the benefits of empagliflozin in heart failure with reduced ejection fraction (HFrEF) and N-terminal pro–B-type natriuretic peptide (NT-proBNP) has not ...

Keywords:

Cardiology
Natriuretic peptide
Empagliflozin
Ejection fraction
Heart failure
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations